These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 28166090)

  • 1. Chemotherapy for recurrent/metastatic head and neck cancers.
    Karabajakian A; Toussaint P; Neidhardt EM; Paulus V; Saintigny P; Fayette J
    Anticancer Drugs; 2017 Apr; 28(4):357-361. PubMed ID: 28166090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
    Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
    BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.
    Soulières D; Faivre S; Mesía R; Remenár É; Li SH; Karpenko A; Dechaphunkul A; Ochsenreither S; Kiss LA; Lin JC; Nagarkar R; Tamás L; Kim SB; Erfán J; Alyasova A; Kasper S; Barone C; Turri S; Chakravartty A; Chol M; Aimone P; Hirawat S; Licitra L
    Lancet Oncol; 2017 Mar; 18(3):323-335. PubMed ID: 28131786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck.
    Wirth LJ; Dakhil S; Kornek G; Axelrod R; Adkins D; Pant S; O'Brien P; Debruyne PR; Oliner KS; Dong J; Murugappan S
    Oral Oncol; 2016 Oct; 61():31-40. PubMed ID: 27688102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of weekly paclitaxel and cetuximab with the EXTREME regimen in the treatment of recurrent/metastatic squamous cell head and neck carcinoma.
    Nakano K; Marshall S; Taira S; Sato Y; Tomomatsu J; Sasaki T; Shimbashi W; Fukushima H; Yonekawa H; Mitani H; Kawabata K; Takahashi S
    Oral Oncol; 2017 Oct; 73():21-26. PubMed ID: 28939072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing treatments for recurrent or metastatic head and neck squamous cell carcinoma.
    Specenier P; Vermorken JB
    Expert Rev Anticancer Ther; 2018 Sep; 18(9):901-915. PubMed ID: 29999437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.
    Wakasaki T; Yasumatsu R; Uchi R; Taura M; Matsuo M; Komune N; Nakagawa T
    Auris Nasus Larynx; 2020 Feb; 47(1):116-122. PubMed ID: 31128940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy for localized head and neck squamous cell cancers.
    Karabajakian A; Toussaint P; Neidhardt EM; Paulus V; Saintigny P; Fayette J
    Anticancer Drugs; 2017 Apr; 28(4):362-368. PubMed ID: 28134662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
    Cho H; Nishiike S; Yamamoto Y; Takenaka Y; Nakahara S; Yasui T; Hanamoto A; Inohara H
    Auris Nasus Larynx; 2015 Oct; 42(5):396-400. PubMed ID: 25721854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck.
    Saada-Bouzid E; Peyrade F; Guigay J
    Curr Opin Oncol; 2019 May; 31(3):146-151. PubMed ID: 30893146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Docetaxel plus cisplatin plus fluorouracil versus carboplatin plus fluorouracil-cetuximab in first-line setting in patients with recurrent or metastatic head and neck squamous cell cancer who did not previously receive neoadjuvant or adjuvant chemotherapy, which is standard?
    Mutlu H; Salim DK; Gündüz Ş; Eryılmaz MK; Musri FY; Coşkun HŞ
    J Cancer Res Ther; 2017; 13(3):510-513. PubMed ID: 28862218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in the management of recurrent or metastatic squamous cell carcinoma of the head and neck.
    Shin DM; Khuri FR
    Head Neck; 2013 Mar; 35(3):443-53. PubMed ID: 22052826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy.
    Siano M; Infante G; Resteghini C; Cau MC; Alfieri S; Bergamini C; Granata R; Miceli R; Locati L; Licitra L; Bossi P
    Oral Oncol; 2017 Jun; 69():33-37. PubMed ID: 28559018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Greenhalgh J; Bagust A; Boland A; Fleeman N; McLeod C; Dundar Y; Proudlove C; Shaw R
    Health Technol Assess; 2009 Oct; 13 Suppl 3():49-54. PubMed ID: 19846029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modified docetaxel, cisplatin and fluorouracil therapy as the first-line treatment for patients with recurrent/metastatic squamous cell carcinoma of the head and neck cancer: a retrospective study.
    Demirci NS; Aksoy S; Özdemir NY; Erdem GU; Ozcelik M; Tanrikulu E; Eren T; Bozkaya Y; Sahin S; Başol F; Aslan SA; Zengin N; Güllü İ
    Curr Med Res Opin; 2017 Mar; 33(3):401-407. PubMed ID: 27817239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current chemotherapies for recurrent/metastatic head and neck cancer.
    Molin Y; Fayette J
    Anticancer Drugs; 2011 Aug; 22(7):621-5. PubMed ID: 21131821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen.
    Soulières D; Aguilar JL; Chen E; Misiukiewicz K; Ernst S; Lee HJ; Bryant K; He S; Obasaju CK; Chang SC; Chin S; Adkins D
    BMC Cancer; 2016 Jan; 16():19. PubMed ID: 26768732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma.
    Kim HS; Kim HR; Kim GM; Kim HS; Koh YW; Kim SH; Choi EC; Hong YK; Sung JH; Kim SM; Kim JH; Cho BC
    Cancer Chemother Pharmacol; 2012 Oct; 70(4):539-46. PubMed ID: 22868340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triweekly reduced-dose docetaxel combined with cisplatin in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase II study.
    Chang PM; Tzeng CH; Chen MH; Tsao CJ; Su WC; Hwang WS; Chang YF; Chang SY; Yang MH
    Cancer Chemother Pharmacol; 2011 Dec; 68(6):1477-84. PubMed ID: 21484308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in paclitaxel-containing chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck.
    Shin DM; Glisson BS; Khuri FR; Ginsberg L; Lawhorn K; Hong WK; Lippman SM
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-33-S19-37. PubMed ID: 9427263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.